Risperidone: a review

Bibliography

• MOLLER HJ: State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J. Biol. Psychiatry (2000) 1:204–214.
   PubMedGoogle Scholar
• MARDER SR: Clinical experience with risperidone. Chit. Psychiatry (1996) 57\(Suppl. 9):57–61.
   Google Scholar
• SERRETTI A, DE RONCHI D, LORENZI C, BERARDI D: New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr. Med. Chem. (2004) 11:343–358.
   PubMed Web of Science ®Google Scholar
• LOVE RC, NELSON MW: Pharmacology and clinical experience with risperidone. Expert. Opia Pharmacother. (2000) 1:1441–1453.
   PubMedGoogle Scholar
• LEYSEN JE, JANSSEN PM, SCHOTTE A, LUYTEN WH, MEGENS AA: Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Ber) (1993) 112:S40–S54.
   Web of Science ®Google Scholar
• GRANT S, FITTON A: Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs (1994) 48:253–273.
   Google Scholar
• NYBERG S, FARDE L, ERIKSSON L, HALLDIN C, ERIKSSON B: 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berl) (1993) 110:265–272.
   PubMed Web of Science ®Google Scholar
• •Demonstrates, using PET, that risperidone occupies 5-HT2 and D2 receptors.
   Google Scholar
• SCHMITT GJ, MEISENZAHL EM, DRESEL S et al: Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine. I Psychopharmacol. (2002) 16:200–206.
   PubMed Web of Science ®Google Scholar
• •Demonstrates, using SPECT, that risperidone occupies 5-HT2 and D2 receptors.
   Google Scholar
• KAPUR S, REMINGTON G, ZIPURSKY RB, WILSON AA, HOULE S: The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. (1995) 57:PL103-PL107.
   Google Scholar
• MOLLER HJ: Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. World J. Biol. Psychiatry (2000) 1:75–91.
   PubMedGoogle Scholar
• NGAN ET, LANE CJ, RUTH TJ, LIDDLE PF: Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naive schizophrenic patients: correlations with symptom change. I Neurol Neurasurg. Psychiatry (2002) 72:106–110.
   PubMed Web of Science ®Google Scholar
• LIDDLE PF, LANE CJ, NGAN ET: Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus. BE I Psychiatry (2000) 177:402–407.
   PubMed Web of Science ®Google Scholar
• DAVIS JM, CHEN N: Dose response and dose equivalence of antipsychotics. Psychophannacol (2004) 24:192–208.
   Web of Science ®Google Scholar
• •Identifies the near-maximal efficacy dose of risperidone as being 4 mg/day.
   Google Scholar
• BERECZ R, DORADO P, DE LA RA, CACERES MC, DEGRELL I, LLERENA A: The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions. Curr. Drug Targets (2004) 5:573–579.
   PubMed Web of Science ®Google Scholar
• PRIOR TI, BAKER GB: Interactions between the cytochrome P450 system and the second-generation antipsychotics. Psychiatry Neurosci. (2003) 28:99–112.
   PubMed Web of Science ®Google Scholar
• BROSEN K, GRAM LF: Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur. I Clin. Phannacol (1989) 36:537–547.
   PubMed Web of Science ®Google Scholar
• SPROULE BA, NARANJO CA, BRENMER KE, HASSAN PC: Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin. Phannacokinet. (1997) 33:454–471.
   PubMed Web of Science ®Google Scholar
• ONO S, MIHARA K, SUZUKI A et al:Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychophannacology (Ber) (2002) 162:50–54.
   PubMed Web of Science ®Google Scholar
• MARDER SR, MEIBACH RC: Risperidone in the treatment of schizophrenia. Am. " Psychiatry (1994) 151:825–835.
   PubMed Web of Science ®Google Scholar
• •Demonstrates better efficacy and tolerability of risperidone compared with haloperidol and placebo.
   Google Scholar
• PEUSKENS J: Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br. I Psychiatry (1995) 166:712–726.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates efficacy and tolerability ofrisperidone compared with haloperidol.
   Google Scholar
• KAY SR, OPLER LA, FISZBEIN A: Positive and negative syndrome scale (PANSS). Rating Manual. Social and Behavioral Documents. San Rafael, CA, USA (1987).
   Google Scholar
• CHOUINARD G, JONES B, REMINGTON G et al: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Clin. Psychophannacol (1993) 13:25–40.
   PubMed Web of Science ®Google Scholar
• MOLLER HJ, MULLER H, BORISON RL, SCHOOLER NR, CHOUINARD G: A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur. Arch. Psychiatry Clin. Neurasci. (1995) 245:45–49.
   PubMed Web of Science ®Google Scholar
• ••Shows that risperidone has direct effects onnegative symptoms.
   Google Scholar
• CHOUINARD G, ROSS-CHOUINARD A, ANNABLE L, JONES BD: The extrapyramidal symptom rating scale. Can. Neurol Li. (1980) 7:233.
   Web of Science ®Google Scholar
• MARDER SR, DAVIS JM, CHOUINARD G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials...! Cita Psychiatry (1997) 58:538–546.
   Google Scholar
• •Demonstrates antidepressive effect of risperidone in schizophrenic patients.
   Google Scholar
• PEUSKENS J, VAN BAELEN B, DE SMEDT C, LEMMENS P: Effects of risperidone on affective symptoms in patients with schizophrenia. Int. Clin. Psychophannacol (2000) 15:343–349.
   PubMed Web of Science ®Google Scholar
• •Shows antidepressive effect of risperidone In schizophrenic patients.
   Google Scholar
• MULLER-SIECHENEDER F, MULLER MJ, HILLERT A, SZEGEDI A, WETZEL H, BENKERT O: Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. I Clin. Psychophannacol (1998) 18:111–120.
   PubMed Web of Science ®Google Scholar
• OSTROFF RB, NELSON JC: Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. Clin. Psychiatry (1999) 60:256–259.
   PubMed Web of Science ®Google Scholar
• FRANZ M, GALLHOFER B: Risperidon - em neuer Serotonin-Dopamin-Antagonist zur Behandlung der Schizophrenie. Psychophannakotherapie (1997) 2:54–58.
   Google Scholar
• GALLHOFER B, BAUER U, LIS S, KRIEGER S, GRUPPE H: Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur. Neuropsychophannacol (1996) 6:13–20.
   PubMed Web of Science ®Google Scholar
• LINDENMAYER JP, ISKANDER A, PARK M et al.: Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J. Clin. Psychiatry (1998) 59:521–527.
   PubMed Web of Science ®Google Scholar
• MELTZER HY, MCGURK SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. (1999) 25:233–255.
   PubMed Web of Science ®Google Scholar
• MCGURK SR, GREEN MG, WIRSHING WC, AMES D, MARSHALL BD, MARDER SM: The effects of risperidone versus haloperidol on spatial working memory in treatment-resistent schizophrenia. Paper presented at 51st Annual Meeting of the Society of Biological Psychiatry, New York, USA (1996).
   Google Scholar
• GREEN ME MARSHALL BD, JR., WIRSHING WC et al: Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am. " Psychiatry (1997) 154:799–804.
   PubMed Web of Science ®Google Scholar
• KERN RS, GREEN ME MARSHALL BD Jr. et al: Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr. Bull. (1999) 25:223–232.
   Google Scholar
• HARVEY PD, NAPOLITANO JA, MAO L, GHARABAWI G: Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int. J. Ceriatr. Psychiatry (2003) 18:820–829.
   PubMed Web of Science ®Google Scholar
• BILDER RM, GOLDMAN RS, VOLAVKA J et al: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am.I Psychiatry (2002) 159:1018–1028.
   PubMed Web of Science ®Google Scholar
• •Demonstrates that risperidone improves global neurocognitive function.
   Google Scholar
• WEISER M, SHNEIDER-BEERI M, NAKASH N et al: Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS? Schizophr. Res. (2000) 46:81–89.
   Google Scholar
• TRAN PV, HAMILTON SH, KUNTZ AJ et al: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Chit. Psychopharmacul (1997) 17:407–418.
   PubMed Web of Science ®Google Scholar
• SCHOOLER NR: Comments on article by Tran and colleagues, Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders'. J. Chit. Psychopharmacul (1998) 18:174–176.
   PubMed Web of Science ®Google Scholar
• CONLEY RR, MAHMOUD R: A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am. J. Psychiatry (2001) 158:765–774.
   PubMed Web of Science ®Google Scholar
• POTKIN SG, SAHA AR, KUJAWA MJ et al.: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone versus placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry (2003) 60:681–690.
   PubMed Web of Science ®Google Scholar
• PEUSKENS J, BECH P, MOLLER HJ, BALER, FLEUROT O, REIN W: Amisulpride versus risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res. (1999) 88:107–117.
   Google Scholar
• SECHTER D, PEUSKENS J, FLEUROT O, REIN W, LECRUBIER Y: Amisulpride versus risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology (2002) 27:1071–1081.
   PubMed Web of Science ®Google Scholar
• ADDINGTON DEN, PANTELIS C, DINEEN M, BENATTIA I, ROMANO SJ: Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. j. Chit. Psychiatry (2004) 65:1624–1633.
   PubMed Web of Science ®Google Scholar
• MULLEN J, JIBSON MD, SWEITZER D: A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clio. Ther. (2001) 23:1839–1854.
   PubMed Web of Science ®Google Scholar
• BONDOLFI G, DUFOUR H, PATRIS M et al.: Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am. I Psychiatry (1998) 155:499–504.
   PubMed Web of Science ®Google Scholar
• •Shows that risperidone is effective in treatment-resistant patients.
   Google Scholar
• WIRSHING DA, MARSHALL BD Jr, GREEN ME MINTZ J, MARDER SR, WIRSHING WC: Risperidone in treatment-refractory schizophrenia. Am. J. Psychiatry (1999) 156:1374–1379.
   PubMed Web of Science ®Google Scholar
• BREIER AF, MALHOTRA AK, SU TP et al: Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am. J. Psychiatry (1999) 156:294–298.
   PubMed Web of Science ®Google Scholar
• EMSLEY RA: Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr. Bull. (1999) 25:721–729.
   PubMed Web of Science ®Google Scholar
• HUQ ZU: A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder. J. Chit. Psychopharmacul (2004) 24:220–224.
   PubMed Web of Science ®Google Scholar
• MERLO MC, HOFER H, GEKLE W et al.: Risperidone, 2 mg/day versus 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. I Chit. Psychiatry (2002) 63:885–891.
   Google Scholar
• APIQUIAN R, FRESAN A, HERRERA K et al: Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine. Int. Neuropsychopharmacul (2003) 6:403–408.
   PubMed Web of Science ®Google Scholar
• MCGORRY PD, YUNG AR, PHILLIPS LJ et al.: Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry (2002) 59:921–928.
   PubMed Web of Science ®Google Scholar
• HECK AH, HAFFMANS PM, DE GROOT IW, HOENCAMP E: Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophr. Res. (2000) 46:97–105.
   PubMed Web of Science ®Google Scholar
• RABINOWITZ J, HORNIK T, DAVIDSON M: Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. I. Chit. Psychiatry (2001) 62:343–346.
   Google Scholar
• LEJEUNE J, LARMO I, CHRZANOWSKI W et al.: Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis. Int. Chit. Psychopharmacul (2004) 19:259–269.
   PubMed Web of Science ®Google Scholar
• CSERNANSKY JG, MAHMOUD R, BRENNER R: A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. (2002) 346:16–22.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates that risperidone is superiorto haloperidol in prevention of relapse.
   Google Scholar
• FENTON WS, BLYLER CR, HEINSSEN RK: Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr. Bull. (1997) 23:637–651.
   PubMed Web of Science ®Google Scholar
• RABINOWITZ J, LICHTENBERG P, KAPLAN Z, MARK M, NAHON D, DAVIDSON M: Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am.Psychiatry (2001) 158:266–269.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates that risperidone is superiorto classical neuroleptics in prevention of relapse.
   Google Scholar
• HARRISON TS, GOA KL: Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs (2004) 18:113–132.
   PubMed Web of Science ®Google Scholar
• ERESHEFSKY L, MASCARENAS CA: Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. Chit. Psychiatry (2003) 64\(Suppl. 16):18–23.
   Google Scholar
• KANE JM, EERDEKENS M, LINDENMAYER JP, KEITH SJ, LESEM M, KARCHER K: Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am.Psychiatry (2003) 160:1125–1132.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates antipsychotic efficacy ofdepot risperidone.
   Google Scholar
• CHUE P, EERDEKENS M, AUGUSTYNS I et al.: Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. Schizophr. (2002) 53:174–175.
   Google Scholar
• ••Demonstrates antipsychotic efficacy ofdepot risperidone.
   Google Scholar
• TAYLOR DM, YOUNG CL, MACES, PATEL MX: Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. ./. Chit. Psychiatry (2004) 65:1076–1083.
   PubMed Web of Science ®Google Scholar
• LASSER RA, BOSSIE CA, GHARABAWI GM, TURNER M: Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur. Psychiatry (2004) 19:219–225.
   PubMed Web of Science ®Google Scholar
• FLEISCHHACKER WW, EERDEKENS M, KARCHER K et al: Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Clin. Psychiatry (2003) 64:1250–1257.
   PubMed Web of Science ®Google Scholar
• HOSALLI P, DAVIS JM: Depot risperidone for schizophrenia. Cochrane Database Syst. Rev (2003) CD004161.
   Google Scholar
• CESKOVA E, SVESTKA J: Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry (1993) 26:121–124.
   PubMed Web of Science ®Google Scholar
• MILLER CH, MOHR F, UMBRICHT D, WOERNER M, FLEISCHHACKER WW, LIEBERMAN JA: The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. I Clin. Psychiatry (1998) 59:69–75.
   PubMed Web of Science ®Google Scholar
• HOYBERG OJ, FENSBO C, REMVIG J,LINGJAERDE O, SLOTH-NIELSEN M, SALVESEN I: Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr. Scand. (1993) 88:395–402.
   PubMed Web of Science ®Google Scholar
• BARAK Y: No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. J. Clin. Psychiatry (2002) 63:117–119.
   PubMed Web of Science ®Google Scholar
• ALLISON DB, MENTORE JL, HEO M et al.: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry (1999) 156:1686–1696.
   PubMed Web of Science ®Google Scholar
• ••Shows that risperidone has a favourableweight gain profile compared with other second-generation antipsychotics.
   Google Scholar
• MCINTYRE RS, TRAKAS K, LIN D et al.: Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can. J. Psychiatry (2003) 48:689–694.
   PubMed Web of Science ®Google Scholar
• GARYFALLOS G, DIMELIS D, KOUNIAKIS P et al.: Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels. Eur. Psychiatry (2003) 18:320–321.
   PubMed Web of Science ®Google Scholar
• LINDENMAYER JP, CZOBOR P, VOLAVKA J et al.: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. Psychiatry (2003) 160:290–296.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry (2004) 65:267–272.
   PubMed Web of Science ®Google Scholar
• ANANTH J, VENKATESH R, BURGOYNE K, GADASALLI R, BINFORD R, GUNATILAKE S: Atypical antipsychotic induced weight gain: pathophysiology and management. Ann. Clin. Psychiatry (2004) 16:75–85.
   PubMedGoogle Scholar
• HUANG ML, VAN PEER A, WOESTENBORGHS R et al: Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol Ther. (1993) 54:257–268.
   PubMed Web of Science ®Google Scholar
• BERSANI G, BRESA GM, MECO G, MARINI S, POZZI F: Combined serotonin-5HT2 and dopamine-D2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64 766). Hum. Psychopharm. (1990) 5:225–231.
   Google Scholar
• MESOTTEN F, SUY E, PIETQUIN M, BURTON P, HEYLEN S, GELDERS Y: Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology (Ber) (1989) 99:445–449.
   PubMed Web of Science ®Google Scholar
• •Shows that risperidone leads to raised prolactin levels.
   Google Scholar
• HENDERSON DC, GOFF DC, CONNOLLY CE, BORBA CP, HAYDEN D: Risperidone added to clozapine: impact on serum prolactin levels. Clin. Psychiatry (2001) 62:605–608.
   PubMed Web of Science ®Google Scholar
• HALBREICH U, KINON BJ, GILMORE JA, KAHN LS: Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology (2003) 28\(Suppl. 1):53–67.
   Google Scholar
• GOODNICK PJ, RODRIGUEZ L, SANTANA O: Antipsychotics: impact on prolactin levels. Expert Opin. Pharmacother. (2002) 3:1381–1391.
   PubMedGoogle Scholar
• LIU GG, SUN SX, CHRISTENSEN DB, LUO X: Cost comparisons of olanzapine and risperidone in treating schizophrenia. Ann. Pharmacother. (2004) 38:134–141.
   PubMed Web of Science ®Google Scholar
• SHAW JW: Economic evaluations of olanzapine and risperidone. Am. I Health Syst. Pharm. (2002) 59:1366–1375.
   PubMed Web of Science ®Google Scholar
• REVICKI DA: Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr. Res. (1999) 35(Suppl.):S101–5109.
   Google Scholar
• ZITO JM: Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. Psychiatr. Clin. North Am. (1998) 21:181–202.
   PubMed Web of Science ®Google Scholar
• DAVIES A, LANGLEY PC, KEKS NA, CATTS SV, LAMBERT T, SCHWEITZER I: Risperidone versus haloperidol: II. Cost-effectiveness. Clin. Ther. (1998) 20:196–213.
   Google Scholar
• FOSTER RH, GOA KL: Risperidone. A Pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics (1998) 14:97–133.
   Google Scholar
• ••Shows favourable cost/benefit ratio forrisperidone.
   Google Scholar
• OH P, EINARSON TR, ISKEDJIAN M, ADDIS A, LANCTOT K: Pharmacoeconomic evaluation of risperidone and clozapine in chronic and treatment-resistant schizophrenia. Canadian Coordinating Office for Health Technol. Assess. (CCOHT A), Ottowa (1996).
   Google Scholar
• GINSBERG G, SHANI S, LEV B: Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel. Pharmacoeconomics (1998) 13:231–241.
   PubMed Web of Science ®Google Scholar
• REVICKI DA: The new atypical antipsychotics: a review of pharmacoeconomic studies. Expert Opin. Pharmacother. (2000) 1:249–260.
   PubMedGoogle Scholar
• REVICKI DA: Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. Curr. Opin. Investig. Drugs (2001) 2:110–117.
   PubMedGoogle Scholar
• BORIS ON RL, PATHIRAJA AP, DIAMOND BI, MEIBACH RC: Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol (1992) 28:213–218.
   Web of Science ®Google Scholar
• HEINRICH K, KLIESER E, LEHMANN E, KINZLER E, HRUSCHKA H: Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Prog. Neuropsychopharmacol. Biol. Psychiatry (1994) 18:129–137.
   PubMed Web of Science ®Google Scholar
• BLIN O, AZORIN JM, BOUHOURS P: Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. I. Chn. Psychopharmacol. (1996) 16:38–44.
   PubMed Web of Science ®Google Scholar
• HUTTUNEN MO, PIEPPONEN T, RANTANEN H, LARMO I, NYHOLM R, RAITASUO V: Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double- blind parallel-group trial. Acta Psychiatr. Scand. (1995) 91:271–277.
   PubMed Web of Science ®Google Scholar
• MOLLER HJ, LAUX G, NABER D et al., Kosten und Effekte von Risperidon in Depotform. Vergliech mit oralen Atypika und konventionellen Depotformulierungen in der Therapie von Schizophrenie-Patienten in Deutschland. Psychopharmakotherapie. (In press).
   Google Scholar